Consensus guidelines on anti-beta 2 glycoprotein I testing and reporting

Pathology

Volumn 40, Issue 1, 2008, Pages 58-63

  Wong, R C W ^a   Favaloro, E J ^b   Adelstein, S ^c   Baumgart, K ^d   Bird, R ^e   Brighton, T A ^f   Empson, M ^g   Gillis, D ^h   Hendle, M J ⁱ   Laurent, R ^j   Mallon, D ^k   Pollock, W ^l   Smith, S ^m   Steele, R H ⁿ   Wilson, R J ^a  

^a ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^b WESTMEAD HOSPITAL   (Australia)

^c ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^d DOUGLASS HANLY MOIR PATHOLOGY   (Australia)

^e PRINCESS ALEXANDRA HOSPITAL   (Australia)

^f PRINCE OF WALES HOSPITAL   (Australia)

^g AUCKLAND CITY HOSPITAL   (New Zealand)

^h INSTITUTE OF MEDICAL AND VETERINARY SCIENCE   (Australia)

ⁱ MATER HOSPITAL   (Australia)

^j ROYAL NORTH SHORE HOSPITAL   (Australia)

^k PathWest Fremantle   (Australia)

^l GRIBBLES PATHOLOGY   (Australia)

^m CANTERBURY HEALTH LABORATORIES   (New Zealand)

ⁿ CAPITAL AND COAST DISTRICT HEALTH BOARD   (New Zealand)

more..

Author keywords

Antibody; Beta 2 glycoprotein I; Consensus; Guidelines; Testing; 2GPI

Indexed keywords

ANTI BETA2 GLYCOPROTEIN 1; GLYCOPROTEIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; UNCLASSIFIED DRUG;

ANTIBODY DETECTION; CALIBRATOR; HUMAN; PRACTICE GUIDELINE; PROTEIN ANALYSIS; PROTEIN DETERMINATION; REVIEW;

EID: 36448996939     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.1080/00313020701717720     Document Type: Article

References (50)

1. McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA 1990; 87: 4120-4.
2. Galli M, Comfurius P, Maassen C, et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990; 335: 1544-7.
3. Matsuura E, Igarashi Y, Fujimoto M, Ichikawa K, Koike T. Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease. Lancet 1990; 336: 177-8.
4. Helbert M, Bodger S, Cavenagh J, et al. Optimising testing for phospholipid antibodies. J Clin Pathol 2001; 54: 693-8.
5. Marai I, Gilburd B, Blank M, Shoenfeld Y. Anti-cardiolipin and anti-beta2-glycoprotein I (beta2GP-I) antibody assays as screening for anti-phospholipid syndrome. Hum Antibodies 2003; 12: 57-62.
6. Audrain MA, Colonna F, Morio F, Hamidou MA, Muller JY. Comparison of different kits in the detection of autoantibodies to cardiolipin and beta2glycoprotein 1. Rheumatology (Oxford) 2004; 43: 181-5.
7. Bertolaccini ML, Gomez S, Pareja JF, et al. Antiphospholipid antibody tests: spreading the net. Ann Rheum Dis 2005; 64: 1639-43.
8. Galli M, Luciani D, Bertolini G, Barbui T. Anti-beta 2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome. Blood 2003; 102: 2717-23.
9. de Laat B, Derksen RH, T UR, de Groot PG. IgG antibodies that recognize epitope Gly40-Arg43 in domain I of beta 2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis. Blood 2005; 105: 1540-5.
10. Pengo V, Biasiolo A, Pegoraro C, et al. Antibody profiles for the diagnosis of antiphospholipid syndrome. Thromb Haemost 2005; 93: 1147-52.
11. Forastiero R, Martinuzzo M, Pombo G, et al. A prospective study of antibodies to beta2-glycoprotein I and prothrombin, and risk of thrombosis. J Thromb Haemost 2005; 3: 1231-8.
12. Zoghlami-Rintelen C, Vormittag R, Sailer T, et al. The presence of IgG antibodies against beta2-glycoprotein I predicts the risk of thrombosis in patients with the lupus anticoagulant. J Thromb Haemost 2005; 3: 1160-5.
13. Wilson WA, Gharavi AE, Koike T, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999; 42: 1309-11.
14. Lockshin MD, Sammaritano LR, Schwartzman S. Validation of the Sapporo criteria for antiphospholipid syndrome. Arthritis Rheum 2000; 43: 440-3.
15. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295-306.
16. Harris EN, Gharavi AE, Patel S, Hughes GRV. Evaluation of the anticardiolipin antibody test: report of an international workshop held April 4 1986. Clin Exp Immunol 1987; 68: 215-22.
17. Harris EN, Pierangeli SS. Revisiting the anticardiolipin test and its standardization. Lupus 2002; 11: 269-75.
18. Favaloro EJ, Wong RC, Jovanovich S, Roberts-Thomson P. A review of beta2-glycoprotein-l antibody testing results from a peer-driven multilaboratory quality assurance program. Am J Clin Pathol 2007; 127: 441-8.
19. Favaloro EJ, Bonar R, Sioufi J, et al. Multi-laboratory testing of thrombophilia: Current and past practice in Australasia as assessed through the RCPA Haematology QAP. Semin Thromb Hemost 2005; 31: 49-58.
20. Favaloro EJ, Silvestrini R. Assessing the usefulness of anticardiolipin antibody assays: a cautious approach is suggested by high variation and limited consensus in multilaboratory testing. Am J Clin Pathol 2002; 118: 548-57.
21. Wong RCW, Favaloro EJ, Pollock W, et al. A multi-centre evaluation of the intra-assay and inter-assay variation of commercial and in-house anti-cardiolipin antibody assays. Pathology 2004; 36: 182-92.
22. Tincani A, Allegri F, Sanmarco M, et al. Anticardiolipin antibody assay: a methodological analysis for a better consensus in routine determinations - a cooperative project of the European Antiphospholipid Forum. Thromb Haemost 2001; 86: 575-83.
23. Neogi T, Gladman DD, Ibanez D, Urowitz M. Anti-dsDNA antibody testing by Farr and ELISA techniques is not equivalent. J Rheumatol 2006; 33: 1785-8.
24. Derksen RH, Bast EJ, Strooisma T, Jacobs JW. A comparison between the Farr radioimmunoassay and a new automated fluorescence immunoassay for the detection of antibodies against double stranded DNA in serum. Ann Rheum Dis 2002; 61: 1099-102.
25. Favaloro EJ, Wong RCW, Silvestrini R, et al. A multi-laboratory peer-assessment quality assurance program based evaluation of anticardiolipin and beta-2-glycoprotein-1 antibody assays. Semin Thromb Hemost 2005; 31: 73-84.
26. Reber G, Schousboe I, Tincani A, et al. Inter-laboratory variability of anti-beta2-glycoprotein I measurement. A collaborative study in the frame of the European Forum on Antiphospholipid Antibodies Standardization Group. Thromb Haemost 2002; 88: 66-73.
27. Reber G, de Moerloose P. Anti-beta2-glycoprotein I antibodies - when and how should they be measured? Thromb Res 2004; 114: 527-31.
28. Wasmuth JC, Oliver y Minarro D, Homrighausen A, et al. Phospholipid autoantibodies and the antiphospholipid antibody syndrome: diagnostic accuracy of 23 methods studied by variation in ROC curves with number of clinical manifestations. Clin Chem 2002; 48: 1004-10.
29. Ichikawa K, Khamashta MA, Koike T, Matsuura E, Hughes GRV. Beta 2-Glycoprotein I reactivity of monoclonal anticardiolipin antibodies from patients with the antiphospholipid syndrome. Arthritis Rheum 1994; 37: 1453-61.
30. Ichikawa K, Tsutsumi A, Atsumi T, et al. A chimeric antibody with the human gamma1 constant region as a putative standard for assays to detect IgG beta2-glycoprotein I-dependent anticardiolipin and anti-beta2-glycoprotein I antibodies. Arthritis Rheum 1999; 42: 2461-70.
31. Wong RCW, Wilson RJ, Pollock W, Steele RH, Gillis D. Anticardiolipin antibody testing and reporting practices among laboratories participating in a large external Quality Assurance Program. Pathology 2004; 36: 174-81.
32. Wong RCW, Gillis D, Adelstein S, et al. Consensus guidelines on anticardiolipin antibody testing and reporting. Pathology 2004; 36: 63-8.
33. Merrill JT. Which antiphospholipid antibody tests are most useful? Rheum Dis Clin North Am 2001; 27: 525-49.
34. Triplett DA. Antiphospholipid antibodies. Arch Pathol Lab Med 2002; 126: 1424-9.
35. Kahles T, Humpich M, Steinmetz H, Sitzer M, Lindhoff-Last E. Phosphatidylserine IgG and beta-2-glycoprotein I IgA antibodies may be a risk factor for ischaemic stroke. Rheumatology (Oxford) 2005; 44: 1161-5.
36. Samarkos M, Davies KA, Gordon C, Loizou S. Clinical significance of IgA anticardiolipin and anti-beta(2)-GP1 antibodies in patients with systemic lupus erythematosus and primary antiphospholipid syndrome. Clin Rheumatol 2006; 25: 199-204.
37. Carmo-Pereira S, Bertolaccini ML, Escudero-Contreras A, Khamashta MA, Hughes GR. Value of IgA anticardiolipin and antibeta2-glycoprotein I antibody testing in patients with pregnancy morbidity. Ann Rheum Dis 2003; 62: 540-3.
38. Lee RM, Branch DW, Silver RM. Immunoglobulin A anti-beta2-glycoprotein antibodies in women who experience unexplained recurrent spontaneous abortion and unexplained fetal death. Am J Obstet Gynecol 2001; 185: 748-53.
39. Greco TP, Amos MD, Conti-Kelly AM, Naranjo JD, Ijdo JW. Testing for the antiphospholipid syndrome: importance of IgA anti-beta 2-glycoprotein I. Lupus 2000; 9: 33-41.
40. Lakos G, Kiss E, Regeczy N, et al. Isotype distribution and clinical relevance of anti-beta2-glycoprotein I (beta2-GPI) antibodies: importance of IgA isotype. Clin Exp Immunol 1999; 117: 574-9.
41. Yamada H, Tsutsumi A, Ichikawa K, et al. IgA-class anti-beta2-glycoprotein I in women with unexplained recurrent spontaneous abortion. Arthritis Rheum 1999; 42: 2727-8.
42. Arkin CF, Adcock DM, Ernst DJ, et al. NCCLS. Collection, Transport, and Processing of Blood Specimens for Testing Plasma-Based Coagulation Assays; Approved Guideline - Fourth Edition. Wayne, PA: NCCLS, 2003; NCCLS document H21-A4.
43. Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. Thromb Haemost 1995; 74: 1185-90.
44. ASCIA Guidelines - Uncertainty of Measurement (inter-batch/lotprecision). Available online at: http://www.allergy.org.au/pospapers/ Uncertainty_of_Measurement.htm (accessed 27 June 2005).
45. Asherson RA, Cervera R. Antiphospholipid antibodies and infections. Ann Rheum Dis 2003; 62: 388-93.
46. Lewis DA, Pound ML, Ortel TL. The reactivity of paired plasma and serum samples are comparable in the anticardiolipin and anti-β2-glycoprotein-1 ELISAs. J Thromb Haemost 2006; 4: 265-7.
47. Wong RC, Favaloro EJ. The reactivity of paired plasma and serum samples are comparable in the anticardiolipin and anti-beta2-glycoprotein-1 ELISAs: a rebuttal. J Thromb Haemost 2006; 4: 1434-5.
48. Lewis DA, Pound ML, Ortel TL. The reactivity of paired plasma and serum samples are comparable in the anticardiolipin and anti-beta2-glycoprotein-1 ELISAs. Reply to a rebuttal. J Thromb Haemost 2006; 4: 1435-7.
49. Agopian MS, Boctor FN, Peter JB. False-positive test result for IgM anticardiolipin antibody due to IgM rheumatoid factor. Arthritis Rheum 1988; 31: 1212-3.
50. Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 2003; 101: 1827-32.